Martha Combs-Woolum, MD
Internal Medicine · Pineville, KYNPI 1033121017
Payments from drug & device makers
Across 207 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$391
- Amgen$332
- Johnson & Johnson$331
- Novo Nordisk$308
- Merck$292
- Astellas Pharma US Inc$175
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,55795%
- Education$1865%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $391 |
| Amgen(2 entities) | 19 | $332 |
| Johnson & Johnson | 18 | $331 |
| Novo Nordisk | 11 | $308 |
| Merck | 18 | $292 |
| Astellas Pharma US Inc | 2 | $175 |
| Axsome Therapeutics, Inc. | 7 | $175 |
| AstraZeneca | 10 | $141 |
| Pfizer | 7 | $135 |
| Bayer | 8 | $134 |
| Lilly USA, LLC | 9 | $116 |
| Novartis | 6 | $109 |
| Abbott | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $93 |
| Phathom Pharmaceuticals, Inc. | 8 | $85 |
| GSK | 4 | $82 |
| Ardelyx, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Vertex | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Medicure Pharma Inc. | 1 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $41 |
| Idorsia Pharmaceuticals US Inc | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Exact Sciences | 2 | $27 |
| Genentech USA, Inc. | 2 | $27 |
| Baxter Healthcare | 1 | $26 |
| Boehringer Ingelheim | 2 | $24 |
| Lundbeck LLC | 1 | $22 |
| Cequr Corporation | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$123
How this compares
$3,743 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $267,925 |
| MounjaroTirzepatide | 165 | $213,755 |
| OzempicSemaglutide | 171 | $176,942 |
| JanuviaSitagliptin Phosphate | 136 | $132,360 |
| XareltoRivaroxaban | 90 | $105,204 |
| KerendiaFinerenone | 70 | $82,410 |
| FarxigaDapagliflozin Propanediol | 89 | $78,267 |
| LinzessLinaclotide | 87 | $75,649 |
| JardianceEmpagliflozin | 63 | $65,304 |
| EntrestoSacubitril/Valsartan | 49 | $57,489 |
| TrulicityDulaglutide | 37 | $45,480 |
| TrintellixVortioxetine Hydrobromide | 58 | $41,134 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $40,186 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $37,005 |
| Repatha SureclickEvolocumab | 55 | $35,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $135 | $286,088307 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $259,235202 claims |
| Novo NordiskOzempic | $308 | $176,942171 claims |
| MerckJanuvia, Janumet | $292 | $145,638149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $141 | $126,725172 claims |
| Johnson & JohnsonXarelto | $331 | $105,20490 claims |
| AbbVieLinzess, Vraylar, Synthroid | $391 | $104,883314 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $24 | $85,345102 claims |
| BayerKerendia | $134 | $82,41070 claims |
| NovartisEntresto | $109 | $57,48949 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $82 | $55,67872 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $41,13458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Pineville
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.